Literature DB >> 25641887

Urinary albumin excretion is increased in patients with rheumatoid arthritis and associated with arterial stiffness.

Karima Becetti1, Annette Oeser1, Michelle J Ormseth1, Joseph F Solus1, Paolo Raggi1, C Michael Stein1, Cecilia P Chung2.   

Abstract

OBJECTIVE: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular disease (CVD). High urinary albumin excretion is a risk factor for CVD in the general population, but its role in atherosclerosis in patients with RA is not well defined.
METHODS: We determined the urine albumin to creatinine ratio (UACR) in 136 patients with RA and 79 controls. Individuals with diabetes or a clinical history of CVD were excluded. We measured coronary artery calcium (CAC) with electron beam computer tomography and augmentation index (AIx) using pulse wave analysis. In patients with RA, erythrocyte sedimentation rate and concentrations of vascular cell adhesion protein-1 (VCAM-1), interleukin 10 (IL-10), C-reactive protein, IL-6, tumor necrosis factor-α, and cystatin-C were measured and results correlated with UACR.
RESULTS: Patients with RA had higher UACR [median (interquartile range): 7.6 (4.0-15.5) mg/g] than control subjects: 5.6 (3.3-9.0) mg/g; p = 0.02. The presence of CAC was not associated with UACR in RA or control subjects. In patients with RA, UACR was significantly correlated with AIx (rho = 0.24, p = 0.01), higher levels of VCAM-1 (rho = 0.2, p = 0.01), and lower levels of IL-10 (rho = -0.2, p = 0.02). The association between AIx and higher UACR remained significant in multivariate analysis [β coefficient of 1.5 (95% CI 0.1-2.8), p = 0.03 that adjusted for age, sex, and race].
CONCLUSION: Urinary albumin excretion was higher in patients with RA than controls and correlated with increased arterial stiffness, higher VCAM-1, and lower IL-10 concentrations.

Entities:  

Keywords:  ARTERIAL STIFFNESS; ATHEROSCLEROSIS; MICROALBUMINURIA; RHEUMATOID ARTHRITIS

Mesh:

Substances:

Year:  2015        PMID: 25641887      PMCID: PMC4383663          DOI: 10.3899/jrheum.141295

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  27 in total

1.  Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation.

Authors:  W F Keane; G Eknoyan
Journal:  Am J Kidney Dis       Date:  1999-05       Impact factor: 8.860

2.  Standards of medical care in diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2005-01       Impact factor: 19.112

3.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

4.  Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with Type 1 diabetes mellitus with microalbuminuria and overt nephropathy.

Authors:  P Clausen; P Jacobsen; K Rossing; J S Jensen; H H Parving; B Feldt-Rasmussen
Journal:  Diabet Med       Date:  2000-09       Impact factor: 4.359

5.  Glomerular and tubular proteinuria as markers of nephropathy in rheumatoid arthritis.

Authors:  C Niederstadt; T Happ; E Tatsis; A Schnabel; J Steinhoff
Journal:  Rheumatology (Oxford)       Date:  1999-01       Impact factor: 7.580

6.  Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.

Authors:  Paul E Stevens; Adeera Levin
Journal:  Ann Intern Med       Date:  2013-06-04       Impact factor: 25.391

7.  Microalbuminuria in patients with rheumatoid arthritis.

Authors:  L M Pedersen; H Nordin; B Svensson; H Bliddal
Journal:  Ann Rheum Dis       Date:  1995-03       Impact factor: 19.103

8.  Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis.

Authors:  Patrick H Dessein; Barry I Joffe; Sham Singh
Journal:  Arthritis Res Ther       Date:  2005-03-24       Impact factor: 5.156

9.  Marked independent relationship between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritis.

Authors:  Patrick H Dessein; Ahmed Solomon; Angela J Woodiwiss; Gavin R Norton; Linda Tsang; Miguel A Gonzalez-Gay
Journal:  Mediators Inflamm       Date:  2013-12-21       Impact factor: 4.711

Review 10.  What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?

Authors:  S C Satchell; J E Tooke
Journal:  Diabetologia       Date:  2008-03-18       Impact factor: 10.122

View more
  5 in total

1.  Serum cystatin C is associated with kidney function but not with cardiovascular risk factors or subclinical atherosclerosis in patients with Systemic Lupus Erythematosus.

Authors:  Patricia Garcia-Garcia; Raquel Castejon; Pablo Tutor-Ureta; R A Silvestre; Susana Mellor-Pita; Carlos Jimenez-Ortiz; Miguel Yebra-Bango
Journal:  Clin Rheumatol       Date:  2017-09-15       Impact factor: 2.980

2.  Albuminuria in Rheumatoid Arthritis: Associations With Rheumatoid Arthritis Characteristics and Subclinical Atherosclerosis.

Authors:  Amanda Sammut; Steven Shea; Roger S Blumenthal; Moyses Szklo; Joan M Bathon; Joseph F Polak; Russell Tracy; Jon T Giles
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-12       Impact factor: 4.794

3.  The role of microalbuminuria as a predictor of subclinical cardiovascular events in rheumatoid arthritis patients and its relation to disease activity.

Authors:  D W Nada; S El Morsy; M H Abu-Zaid; M A Aboelhawa; Mohammad A Zakaria; E A El Sheikh; R A Gaber
Journal:  Clin Rheumatol       Date:  2017-10-23       Impact factor: 2.980

4.  Urinary albumin excretion in patients with rheumatoid arthritis in a large cross-sectional study.

Authors:  Herwig Pieringer; Kathrin Danninger; Rudolf Puchner; Uta C Hoppe; Erich Pohanka
Journal:  Clin Rheumatol       Date:  2016-06-24       Impact factor: 2.980

5.  Association between urinary sodium and potassium excretion and blood pressure and inflammation in patients with rheumatoid arthritis.

Authors:  Daniel Carranza-Leon; Rany Octaria; Michelle J Ormseth; Annette Oeser; Joseph F Solus; Yahua Zhang; Chimalum R Okafor; Jens Titze; C Michael Stein; Cecilia P Chung
Journal:  Clin Rheumatol       Date:  2017-12-14       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.